Sargramostim inhalation

Drug Profile

Sargramostim inhalation

Alternative Names: Aerosol sargramostim; GM-CSF inhalation; Granulocyte-macrophage colony-stimulating factor -Aerosol formulation; Sargramostim - aerosol formulation

Latest Information Update: 10 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Class Adjuvants; Chemoprotectants; Granulocyte-macrophage colony-stimulating factors
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Macrophage stimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Lung cancer

Most Recent Events

  • 19 Jul 2013 Biomarkers information updated
  • 10 Dec 2007 Discontinued - Phase-I for Lung cancer in USA (Inhalation)
  • 20 Jul 2006 No development reported - Phase-I for Lung cancer in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top